Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.

Yoshitaka SaitoYoh TakekumaMasaki KobayashiYoshito KomatsuMitsuru Sugawara

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)

We found that a low platelet level at baseline was a risk factor, whereas dose reduction from initiation was a preventive factor in regard to treatment suspension and severe neutropenia occurrence in GEM + nab-PTX treatment.

Keyphrases

risk factors
risk assessment
squamous cell carcinoma
combination therapy
advanced non small cell lung cancer
radiation therapy
epidermal growth factor receptor
sensitive detection